Description
The global Endometriosis market estimated at US$2.7 Billion in the year 2024 is now projected to grow at a CAGR of 4.1% and reach US$3.82 Billion by 2030.
The research report provides a comprehensive review of market trends, market growth drivers, PEST Analysis, Market growth inhibitors, and strategic industry activities and SWOT Analysis of key players in the market.
The report provides market estimates and forecast for geographic markets such as the North America (US, Canada, Mexico and Rest of North America), South America (Brazil, Argentina and Rest of South America), Europe (Germany, France, U.K., Russia, Italy, Spain, Sweden, Netherlands, Poland, Austria, Norway, Switzerland, Denmark and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Taiwan, India, Australia and Rest of Asia-Pacific), Middle East (Iran, Turkey, Kuwait, UAE, Israel and Rest of Middle East) & Africa.
Key players profiled in the report include Abbott Laboratories; AbbVie Inc.; Astellas Pharma Inc.; AstraZeneca Plc; Bayer AG; Debiopharm Group; ElexoPharm; EndoCeutics; Evotec AG; Kissei Pharmaceutical Co. Ltd.; Meditrina Pharmaceuticals Inc.; Myovant Sciences; Neurocrine Biosciences Inc.; ObsEva SA; Pfizer Inc.; Repros Therapeutics Inc.; Takeda Pharmaceutical Company Limited; ValiRx plc among others.
